A 50-year-old woman with BMI 37 kg/m² and T2D asks about weight-loss pharmacotherapy. Which option has the strongest evidence for ≥10% weight loss wit...

Question

A 50-year-old woman with BMI 37 kg/m² and T2D asks about weight-loss pharmacotherapy. Which option has the strongest evidence for ≥10% weight loss with cardiometabolic benefit?

Accepted Answer

GLP-1 receptor agonist (e.g., semaglutide)

Answer

Orlistat

Answer

Topiramate monotherapy

Answer

Phentermine short-term

Answer

Bupropion alone

us-abim MCQ (SBA): Obesity pharmacotherapy

A 50-year-old woman with BMI 37 kg/m² and T2D asks about weight-loss pharmacotherapy. Which option has the strongest evidence for ≥10% weight loss with cardiometabolic benefit?